Stoke Therapeutics (STOK) Shares Outstanding (Weighted Average) (2018 - 2026)

Stoke Therapeutics has reported Shares Outstanding (Weighted Average) for 9 years, with the latest figure at $63.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 8.99% year-over-year to $63.1 million; the trailing twelve-month figure through Mar 2026 stood at $63.1 million (up 8.99% YoY), and the FY2025 full-year result was $59.2 million, up 9.65% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $63.1 million, up from $59.2 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $63.1 million in Q1 2026, with the low at $37.4 million in Q1 2022.
• Average Shares Outstanding (Weighted Average) over 5 years is $49.0 million, with a median of $46.2 million recorded in 2024.
• Year-over-year, Shares Outstanding (Weighted Average) gained 2.2% in 2022 and rose 27.28% in 2024.
• Tracing STOK's Shares Outstanding (Weighted Average) over 5 years: stood at $38.9 million in 2022, then rose by 13.1% to $44.0 million in 2023, then advanced by 22.76% to $54.0 million in 2024, then rose by 9.65% to $59.2 million in 2025, then rose by 6.49% to $63.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $63.1 million (Q1 2026), $59.2 million (Q4 2025), and $58.3 million (Q3 2025), per Business Quant data.

Peer Comparison